Get Connected:


Latest Headlines

EV-D68: Will Last Year's Outbreak Be Repeated?
Enterovirus D68 caused hundreds of hospitalizations and five deaths across the US in 2014. It left many mysteries, including why so many people got it since a CDC study showed the US populace is basically immune the virus, one discovered in 1962. Why it was linked to paralysis in some children is also unclear. But three experts at ID Week 2015 today agreed, EV-D68 will be back.
Study Finds Only Half of Patients on Antiretroviral Therapy Receive Recommended Regimens
Patients on non-recommended treatment regimens are less likely to achieve viral suppression and more likely to report side effects.
Longer Interval Between HIV Screening Affects CD4+ Counts at the Time of Diagnosis
Researchers report that waiting more than 2 years between HIV screenings is associated with double the rate of AIDS by CD4+ criteria at the time of HIV diagnosis when compared with more frequent testing.
Implementing Federal Recommendations for HIV Prevention Will Reduce New HIV Infections and HIV-Related Illness
The new guidelines provide important updates in four key areas, including behavioral screening for possible HIV transmission, sexually transmitted disease screening and treatment, HIV partner services, and referral for medical and social services.
Q&A With Jeffrey Cohen From Cleveland Clinic: ECTRIMS Provides Global View of Multiple Sclerosis Today And In the Future
The ECTRIMS conference may be based in Europe but as the conference has grown so has its global impact on multiple sclerosis treatment. With topics ranging from newly approved therapies to those in the pipeline to those not yet ready for testing there is lots to learn in the yearly event.
Q&A With Ayman Tourbah From University Hospital of Reims: Treatment For Progressive Multiple Sclerosis Still Lags Behind Relapsing Form
In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.
Positive Pivotal Study Results with Ocrelizumab for Two Forms of Multiple Sclerosis
A pair of phase III studies revealed positive efficacy and safety outcomes for ocrelizumab, and this could be a game-changer for patients with multiple sclerosis (MS).

Most Popular

Featured Audio

Moderator Tom Wilson asks each panelist to share his thoughts and predictions on what he sees happening to the Affordable Care Act in the next 12 months.
This is one segment in two expert physicians’ discussion of Ebola taped in our Plainsboro, NJ studio. To view all the segments, click here.
$vacMongoViewPlus$ $vAR$